Why Biohaven Stock Was Rocking the Market This Week

The past few business days have been eventful for Biohaven (NYSE: BHVN). The company, which, in its present incarnation, is a clinical-stage biotech, agreed to an impressive licensing and collaboration deal with a peer and secured a favorable judgment in a court case.These factors helped propel Biohaven stock to a more than 16% gain week to date as of Friday before market open, according to data compiled by S&P Global Market Intelligence.Of the two developments, the more impactful was that agreement. Early Wednesday morning, Biohaven announced that South Korea-based SK Biopharmaceuticals will compensate it with up to $795 million in upfront and milestone payments for an exclusive worldwide license to its Kv7 ion channel platform. Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool